Nelfinavir Mesylate and Bortezomib in Treating Patients With Relapsed or Progressive Advanced Hematologic Cancer

DISEASE CHARACTERISTICS:

* Diagnosed with advanced hematologic malignancies meeting the following criteria:

  * Multiple myeloma

    * Received ≥ 2 lines of prior chemotherapy (induction chemotherapy followed by high-dose chemotherapy and autologous stem cell transplant with or without maintenance therapy is considered one line of therapy)
  * Acute myeloid leukemia
  * Acute lymphoblastic leukemia
  * Diffuse large B-cell lymphoma
  * Hodgkin lymphoma
  * Mantle cell lymphoma
  * Mature T- and NK-cell neoplasms restricted to the following WHO-defined entities:

    * T-cell prolymphocytic leukemia
    * T-cell large granular lymphocytic leukemia
    * Aggressive NK-cell leukemia
    * Adult T-cell leukemia/lymphoma
    * Extranodal NK/T-cell lymphoma (nasal type)
    * Mycosis fungoides
    * Sézary syndrome
    * Primary CD30-positive T-cell lymphoproliferative disorders
    * Primary cutaneous anaplastic large cell lymphoma
    * Primary cutaneous gamma-delta T-cell lymphoma
    * Peripheral T-cell lymphoma (not otherwise specified)
    * Angioimmunoblastic T-cell lymphoma
    * Anaplastic large cell lymphoma (ALK-positive/ALK-negative)
  * Grade 3B follicular lymphoma
* Relapsed following or progressed during standard therapy
* Meeting the following criteria:

  * Standard intensive therapy is not feasible
  * Current disease state for which there is no standard effective therapy
  * Refused standard therapy where no curative option exists
* Measurable disease, defined as the following:

  * Myeloma: measurable serum monoclonal protein \> 1 g/dL for IgG, or \> 0.5 g/dL for IgA, IgM or IgD, or difference between involved and uninvolved free light chain levels in serum \> 100 mg/L
  * Lymphoma: must have ≥ 1 lesion measurable by CT (longest diameter ≥ 15 mm)
  * Acute leukemia: ≥ 20% blasts in bone marrow or in peripheral blood (≥ 200/mL blasts in peripheral blood)
* No HIV-associated lymphoma

PATIENT CHARACTERISTICS:

* WHO performance status 0-2
* Absolute neutrophil count ≥ 1,500/mm³
* Platelet count ≥ 75,000/mm³ (if bone marrow impairment, ≥ 20,000/mm\^3)
* Hemoglobin \> 80 g/L (if considered to be caused by the underlying hematologic malignancy or bone marrow impairment, \> 80 g/L after transfusion)
* Bilirubin ≤ 1.5 times upper limit of normal (ULN) (if suspected hemolysis, direct bilirubin ≤ 1.5 times ULN)
* ALT ≤ 2.5 times ULN
* Calculated creatinine clearance \> 30 mL/min
* Not pregnant or nursing
* Negative pregnancy test
* Fertile patients must use effective contraception during and for 12 months after completion of study treatment
* Willing and capable to comply with an oral regimen
* Capable of understanding information given by the investigator on the trial
* Able to adhere and remain in geographic proximity to allow proper staging, treatment, and followup
* No other non-hematologic malignancy within the past 5 years, except adequately treated cervical carcinoma in situ or localized nonmelanoma skin cancer
* No known chronic hepatitis B or C infection or known HIV infection
* No serious underlying medical condition (at the judgment of the investigator) which would impair the ability of the patient to participate in the trial, including any of the following:

  * Active autoimmune disease
  * Uncontrolled diabetes
  * Ongoing or active infection
  * Symptomatic congestive heart failure
  * Unstable angina pectoris
  * Cardiac arrhythmia
  * Psychiatric disorder
* No myocardial infarction within the past 6 months
* No polyneuropathy \> grade 1 significantly interfering with activities of daily living or painful polyneuropathy
* No known hypersensitivity to trial drugs or hypersensitivity to any other component of the trial drugs

PRIOR CONCURRENT THERAPY:

* See Disease Characteristics
* No more than 4 prior lines of chemotherapeutic regimens (induction chemotherapy followed by high-dose chemotherapy and autologous stem cell transplant with or without maintenance therapy is considered one line of therapy)
* More than 30 days since prior treatment in a clinical trial
* More than 30 days since prior and no concurrent chemotherapy or biologic agents

  * For patients with acute leukemia, hydroxyurea may be given up to 48 hours before first administration of the trial treatment, and low dose cytarabine (up to 20 mg/m\^2) and mitoxantrone up to 20 mg up to 14 days before first dosing
* At least 1 week since prior and no concurrent CYP3A4 modulators
* No concurrent other experimental drugs
* No concurrent radiotherapy
* No concurrent antineoplastic therapy with chemotherapeutic or biologic agents